Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., . . . Pazdur, R. (2017). FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy. Oncologist.
Citação norma ChicagoLarkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Disease Progression On or After Platinum‐Containing Chemotherapy." Oncologist 2017.
Citação norma MLALarkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Disease Progression On or After Platinum‐Containing Chemotherapy." Oncologist 2017.